Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease

Table 3 Baseline characteristics of study participants compared by metabolic dysfunction-associated steatohepatitis grade

	Grade 0 (n = 22)	Grade 1 (n = 66)	Grades 2 and 3 (n = 11)	Total (n = 99)
Age	55.6 ± 2.6	56.8 ± 1.5	58.2 ± 3.9	56.7 ± 1.2
Sex (female/total) (%)	8/22 (36)	32/66 (48)	7/11 (64)	4799 (47)
BMI	32.3 ± 1.3	34.8 ± 1.1	34.7 ± 2.2	34.3 ± 0.8
Alc	6.44 ± 0.4	6.48 ± 02	6.56 ± 0.4	6.48 ± 0.2
Diabetes (yes/total) (%)	8/22 (36)	33/65 (51)	5/11 (45)	46/98 (47)
Hypertension (yes/total) (%)	1222 (55)	36/64 (56)	9/11 (82)	57/97 (59)
Dysipidemia (yes/total) (%)	11/22 (50)	36/57 (63)	9/10 (90)	56/89 (63)
FIB-4	2.36 ± 0.5	3.13 ± 0.4	2.04 ± 0.5	2.83 ± 0.3
NAFLD fibrosis score	-0.176 ± 0.6	0.0329 ± 0.3	-0.705 ± 0.7	-0.0996 ± 0.2

Data presented as mean ± SEM. One-way ANOVA test used for age and non-alcoholic fatty liver disease fibrosis score comparisons. Kruskal-Wallis test was used for body mass index, A1c, and fibrosis-4 comparisons. The χ² test was used for sex, the presence of diabetes, the presence of hypertension, and the presence of dyslipidemia comparisons. BMI: Body mass index; FIB-4: Fibrosis-4; NAFLD: Non-alcoholic fatty liver disease.